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Factor Xllla-positive dermal dendritic cells and
HLA-DR expression in radial versus vertical
growth-phase melanomas
Fifty nevomelanocytic lesions, including 10 typical compound
nevi and 20 radial and 20 vertical growth-phase melanomas, were
evaluated for factor Xllla and HLA-DR (I.N3) expression within
dermal dendritic cells (DDCs) or dermal dendrocytes to deter-
mine if DDCs proliferate and/or participate a.s possible antigen-
])resenting cells in the local tisstie response to benign and malig-
nant nevomelanocytic lesions. There was no statistical difference
in factor Xllla staining of DDCs between ne\i and radial or verti-
cal growth-phase melanomas, suggesting that DDCs do not signif-
icantly proliferate in novomelanocytic lesions. However, studies to
determine proliferation rate, apoptosis, and influences of local
mediators on cell growth and/or recruitment were not done.
HLA-DR staining by DDCs was significantly increased (p<0.001)
ill both melanoma groups when compared to compound nevi,
but did not significantly differ between radial and vertical growth-
phase melanoma.s. The intensity of HL;\-DR expression appeared
to correlate with the presence or absence of lymphocytic inflam-
mation; HLA-DR intensity was judged greater in melanomas char-
acterized by a brisk and infiltiative lymphocytic host response. We
propose that DDCs may participate in the dermal iniinune re-
sponse to invasive melanomas, probably as antigen-presenting
cells to skin-as.sociated lymphocytes.
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Dermal dendritic cells (DDCs) or dermal dendro-
cytes are normal resident cells of the reticular der-
mal interstitium, occurring predominantly
perivasculaiiy and within the papillary dermis.
They are characterized by their highly dendritic
morphology (1). Although the origin of the DDC
remains a topic of debate, the preponderance of
e\idence from immunohistochemistry and im-
munofluorescence studies supports their deriva-
tion from bone marrow progenitor cells (2, 3).
Most DDCs express cytoplasmic factor Xllla, a
protransglutaminase involved in hemostasis (4—6).
In addition tt> their putative role in wound heal-
ing, DDCs are capable of phagocytosis of hemo.si-
derin, melanin, and exogenous pigments, such as
are present in tattoos (1, 4, 7).
DDCs proliferate in a variet)' of inflammatory
and neoplastic processes. In inflammatory derma-
toses, such as psoriasis and atopic eczema, an in-
crease in DDCs associated with a lymphocytic infil-
trate was previously reported (3). A proliferation of
factor Xllla-positive DDCs is the sine qua non of
the dermatofibioma, and is also seen in fibrous pa-
pules of the face (8. 9). Moreover, DDC^ are readily
identified at the periphery of Kaposi's sarcomas
(10). Denton et al. evaluated the distribution of fac-
tor XII la-positive DDCs in di.stinguishing nodtilar
melanomas from Spitz nevi (11). Tbey demonstrat-
ed tbat DDCs were either diffusely distributed with-
in the tumor or primarily localized to the periph-
ery, and that the pattern of distribution could not
be used to distinguish between these two entities.
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A proposed antigen-presenting role for DDCs is
based on their proliferation and enhanced expres-
sion of HLA-DR, a class II, nonconsdtutively ex-̂
pressed major histocompatibility antigen, in intra-
dermal delayed hypersensitivity reactions (1) and
as potent stimulators of allogeneic mixed lym-
phocyte reactions in vitro (12). Although HLA-DR
expression in melanomas has been extensively
studied, the primary focus has been on antigen ex-
pression in melanoma cells (13-19). A few groups
have evaluated HLA-DR expression by dendritic
cells (Langerhans cells) residing within the dermis
(20, 21); however, to our knowledge, differences
in HLA-DR expression by factor Xllla-positive
DDCs in radial versus vertical growth-phase
melanomas has not been done.
In this study, we semiquantitatively evaluated
factor Xllla expression by DDCs in benign and
malignant nevomelanocytic lesions to determine
if there was a hypei^plasia of DDCs and, if so,
whether there specifically was a difference be-
tween radial and vertical growth-phase melano-
mas. Moreover, we assessed HLA-DR expression by
DDCs to delineate a possible immunologic role as




Fifty cases, 20 radial and 20 vertical growth-phase
melanomas and 10 typical compound nevi, were
obtained through the Melanoma Clinic registry
and the SNOMED retrieval program of the Pathol-
ogy Data Systems of the University of Michigan
Medical Center. Cases were excluded if they were
re-excisions of a previously diagnosed melanoma
or compound nevus.
Radial were compared to vertical growth-phase
melanomas for sex, age, body site, presence or ab-
sence of regression, and sun exposure. There were
more males than females in the radial growth-
phase group (14 vs. 6), as opposed to slightly more
females than males in the vertical growth-phase
group (11 vs. 9). The mean age was not apprecia-
bly different between the two groups (radial, 56
years; vertical, 61 years). Melanomas were separat-
ed into sites as follows: head and neck (radial, 4;
vertical, 5), trunk (radial, 12; vertical, 8), extremi-
ties (radial, 3; vertical, 7), and site not provided
(radial, 1). Presence of regression did not differ
between the two groups (radial, 5; vertical, 4). In
cases with regression, it was either focal (radial, 1;
vertical, 2), or diffuse (radial, 4; vertical, 2). The
degree of sun exposure was determined based on
the degree of elastosis seen on the original hema-
toxylin and eosin stained slides. There was no sig-
nificant difference between radial or vertical
growth-phase melanomas with respect to presence
(radial, 14; vertical, 15), or degree of elastosis.
Immunoperoxidase methods
Four-pm sections of formalin-fixed, paraffin-em-
bedded tissue were prepared on plus slides (Bax-
ter Scientific). In the vast majority of cases, se-
quential slides were prepared at approximately 4-
|im intervals and consecutively stained with the
primary antibodies in question.
Single iabeiing
The slides were deparaffinized in xylene and etha-
nol. Endogenous peroxidases were blocked with
hydrogen peroxide. Pretreatment with protease
was done for factor Xllla and CDla stains, and mi-
crowave for CD34 (HPCA-1/2) stains; no pretreat-
ment was done for HLA-DR (LN3). The tissues
were stained with piimary antibody followed by a
biotinylated, polyspecific secondary antibody and
an avidin-biotin horseradish peroxidase amplifi-
cation system using an automated (Ventana)
method. Each case was stained with a 1:800 dilu-
tion of rabbit polyclonal antibody to factor Xllla
(Becton-Dickinson), an undiluted mouse mono-
clonal antibody to HLA-DR (BioGenex), an undi-
luted mouse monoclonal antibody to CDla (Im-
munotecli), and a 1:10 dilution of mouse mono-
clonal antibody to CD34 (Becton-Dickinson). The
peroxidase was visualized with 3 ,3'-diaminoben-
zadine (DAB). All slides were counterstained with
Mayer's hematoxylin. Each antibody was applied
to all 50 cases in a single run to avoid interbatch
variability.
Double iabeiing
Six cases, three radial and three vertical growth-
phase melanomas, were double labeled with HLA-
DR vs. factor Xllla, HLA-DR vs. CD34, and CD34
vs. factor Xllla. The slides were deparaffinized as
above. Endogenous peroxidases were blocked
with hydrogen peroxide. Microwave pretreatment
was performed for optimal antigen retrieval of
HLA-DR. factor Xllla, and CD34, as determined
by single stain control runs using different forms
of pretreatment, i.e. no pretreatment, enzyme pre-
treatment, or microwave pretreatment. The tissues
were stained with the first primary antibody (HLA-
DR for HLA-DR vs. factor Xllla or HLA-DR vs.
CD34, or CD34 for CD34 vs. factor Xllla) at the
same titers as above, followed by a biotinylated,
polyspecific (anti-mouse and anti-rabbit) second-
ary antibody and an avidin-biotin horseradish
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Hg. I. Slightly increased (1+) factor Xllla-positive staining of
DDCs in a case of radial growth-phase melanoma (Immu-
noperoxidase, 115x).
peroxidase amplification system by an automated
(Ventana) method. The peroxidase reaction prod-
uct was detected using DAB. The slides were then
subjected to the second primary antibody (factor
Xllla or CD34 for HLA-DR, or factor Xllla for
('D34) followed by a biotinylated, polyspecific (an-
ti-mouse and anti-rabbit) secondary antibody and
an avidin-biotin alkaline phosphatase amplifica-
tion system also using an automated (Ventana) sys-
tem. The alkaline phosphatase reaction product
was detected using fast red. All slides were coun-
terstained with Mayer's hematoxylin.
Interpretation of stains
Factor XlUa, HLA-DR, CD-34, and CDla slides
were interpreted for staining intensity and scored
semiquantitatively on a scale of 0-3-H. The scoring
system for staining intensity was as follows: 0
(none) = rare to no cells staining; \+ (slight) = low
density, patchy staining; 2+ (moderate) ^ moder-
ate density, focal or confluent paralesional stain-
ing; and 34- (marked) = high density with broad,
confluent paralesional staining. Care was taken to
exclude melanin-containing macrophages (melan-
ophages) as a source of false positive staining.
Moreover, distinguishing lymphocyte from DDC
staining with HLA-DR was important in avoiding a
false positive interpretation; this was readily
achieved on morphologic grounds.
Statisticai anaiysis
Chi-square analysis was performed using Sigma
Stat 2.0 .software (Jandel Scientific, San Raphael,
Ca) run on a Compaq Desk pro 590 PC. Statistical
significance was assigned at the p<0.05 level.
Fig. 2. .Sliglil (IT) lilA-DR (LN3) slainiiig of DDCs in a t;a.se of
radial growth-phase inelaiioiiia (Iiiinitinopcroxidase, n5x).
Results
Factor Xiiia staining
Four of 10 (40%) compound nevi, 9 of 20 (45%)
radial growth-phase melanomas, and 12 of 20
(60%) vertical growth-phase melanomas showed
an increase in factor Xllla staining of DDCs (Ta-
ble 1). The majority of cases, with the exception of
3 vertical growth-phase melanomas, had only
slight (1-I-) increased staining (Fig. 1). Wlien com-
pared to compound nevi, there was no statistical
difference in factor Xllla staining for radial
(p=1.00) or vertical (p=0.44) growth-phase
melanomas.
HLA-DR staining
Two of 10 (20%) compound iie\i and 17 each of
20 (85%) radial and vertical growth-phase
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Fig. 3. Moderate (2+) HLA-DR staining of DDCs in a t:a.>ii.' of
vertical growth-phase melanoma. Note the association of posi-
tive staining DDCs with the brisk inflammatory lymphocytic in-
filtrate (Imniunoperoxidase, 115x).
melanomas showed HLA-DR expression by DDCs
(Table 2). The majority of cases showed slight
HLA-DR staining (Fig. 2). However, in 7 of 17
(41%) radial and 6 of 17 (35%) vertical growth-
phase melanomas, the intensity of staining was
judged to be moderate (2+) (Fig. 3). HLA-DR ex-
pression was judged to be similar in both melano-
ma groups, but was significantly increased in both
melanoma groups when compared to compound
nevi (p<0.001). Of particular interest, HLA-DR ex-
pression by DDCs appeared to correlate with the
presence or absence of a lymphocytic infiltrate in
both radial and vertical growth-phase melanomas.
Furthermore, the intensity of staining was greater
in the presence of a brisk and infiltrative lym-
phocytic host response, whereas the intensity of
staining was less or absent in a nonbrisk and non-
infiltrative or absent lymphocytic host response
(Fig. 3).
CD1 a Staining
Two of 10 (20%) compound nevi, 3 of 20 (15%)
radial growth-phase melanomas, and 5 of 20 (25%)
vertical growth-phase melanomas demonstrated
slight (1+) increased CDla staining of cells in the
superficial dermis (Table 3). There was good inter-
nal control staining of CDla-positive Langerhans
cells within the epidermis. The Langerhans cells
within the derinis tended to cluster as a few cells
around blood vessels in association with a lym-
phocytic infiltrate of variable intensity. However,
most lesions demonstrating a lymphocytic host re-
sponse, including both radial and vertical growth-
phase melanomas, did not show cells staining for
CDla within the dermis. Based on the few cases
with CDla-positive cells in the derinis and the
small number of cells that were tighdy distributed
around blood vessels in a very focal pattern, it is
apparent that these cells did not significantly con-
tribute to the HLA-DR expression seen iti DDCs.
CD34 staining
Seven of 10 (70%) and 2 of 10 (20%) compound
nevi showed slight (l-i-) and moderate (2+) CD34
staining, respectively. Eight of 20 (40%), 6 of 20
(30%), and 3 of 20 (15%) radial growth-phase
melanomas showed slight, moderate, and marked
CD34 staining, respectively. No vertical growth-
phase melanomas had marked staining; however,
5 of 20 (25%) had slight and 5 of 20 (25%) had
moderate staining (Table 4). DDCs that stained
with CD34 had morphologic features indistin-
guishable from factor Xllla-positive DDCs, al-
thotigh those CD34-positive DDCs within the in-
terstitium tended to be more evenly distributed
from upper to deep dermis. When increased stain-
ing was observed, it was usually seen within DDCs
along the base or periphery of the lesion. CD34-
positive DDCs were located both perivascularly
and within the dermal interstitium. As expected,
CD34 also stained endothelial cells, as well as den-
dritic cells within the connective tissue surround-
ing eccrine coils. Since the vascularity varied, in
some cases significantly, from case to case, no at-
tempt was made to factor out the contribution of
vascular staining to the total score, as reproducibil-
ity would be difficult to achieve.
Double labeling
In 4 of 6 melanoma cases (radial, 2; vertical, 2) on
which double labeling for HLA-DR vs. factor Xllla
was performed, frequent factor Xllla-positive
DDCs coexpressing HLA-DR weie seen (Fig. 4).
There did not appear to be a difference between
radial and vertical growth-phase melanomas in
number of DDCs staining with both factor Xllla
and HLA-DR. However, there were other cells,
mosdy lymphocytes but occasional factor Xllla-
negative DDCs, expressing only HLA-DR. Occa-
sional factor Xllla-positive DDCs did not show
HLA-DR coexpression. Two cases showed strong
HLA-DR staining but very weak and patchy factor
Xllla staining; these cases were considered unreli-
able for interpretation. It is possible that antigen
retrieval for factor Xllla by microwaving was sub-
optimal on these two cases.
When CD34 and factor Xllla were applied in
our double labeling techniqtie, DDCs were readily
identified with restricted staining for either CD34
or factor Xllla in 3 of 6 cases (Fig. 5). No DDCs co-
expressiug both epitopes were seen. In 3 of 6 cases,
CD34 stained DDCs well; however, factor Xllla
556
Factor Xllla-positive dermal dendritic cells and HLA-DR expression
fable 3. Results ot CDla staining ot cells wittiin the dermis.
Fig. 'f. Perivascular factor Xllla-posidve (red) DDCs demon-
.strating coexpression of HLA-DR (browii) by double labeling
(Immunoperoxidase, 825x).
\
Fig. 5. Restricted slainiiig oi C;D.S4 (brown) within endothelial
cells and occasional heinatopoietic cells, and factor Xllla (red)
within DDCs (Immunoperoxidase, 528x).
Staining was weak and focal. Therefore, as with a
few cases of HLA-DR vs. factor Xllla, these cases
were considered unreliable for interpretation.
CD34 was stained against HLA-DR to see if any
CD34-positive DDCs may coexpress HLA-DR, pos-
sibly accounting for the occasional DDCs express-
ing HLA-DR that were factor XIIla-negative. Five
of 6 cases showed strong staining for both HLA-
DR and CD34. No CD34 DDCs were observed to
coexpress HLA-DR. In one case, HLA-DR staining
was strong btit CD34 staining was absent. There-
fore, this case was considered unreliable for inter-
pretation.
Discussion
In contrast to fibroproUferative lesions, such as
dermatofibromas or fibrous papules of the face,
(here was no significant hyperplasia of DDCs, as
determined by cytoplasmic factor Xllla labeling,




































postulate that DDCs would be increased above
background in invasive melanomas when com-
pared to a benign nevomelanocyt:ic control group
was not confirmed in this study. Moreover, if DDCs
increased in invasive melanomas, either due to
proliferation or recruitment, we hypothesized that
the number of DDCs would be either unchanged
or, more likely, reduced in vertical growth-phase
melanomas when compared to radial growth-
phase melanomas. We found no difference in the
number of factor XIIla-positive DDCs between ver-
tical and radial growth-phase melanomas, as deter-
mined semiquantitatively.
Radial and vertical growth-phase melanomas
are associated with a significantly increased ex-
pression of HLA-DR by DDCs in single antibody
immunoperoxidase studies, suggesting that DDCs
may have an antigen-presenting role in the dermal
immune response to invasive melanomas. This is
perhaps not surprising, since HLA-DR expression
hy DDCs in inti"adermal delayed hypersensitivity
reactions has been described (1). In order to con-
firm that factor Xllla-positive cells may coexpress
HLA-DR, we subjected a small subset of radial and
vertical growth-phase melanomas to an immuno-
peroxidase double labeling technique. We found
that some factor Xllla-positive DDCs coexpress
HLA-DR (cells with cytoplasmic staining for both
antigens), thereby confirming our impression
from single antibody studies. We acknowledge the
remote possibility of cross reacti\'ity in our double
labeling experiment, since the secondary antibody
used against both primary antibodies was polyspe-
cific. However, based on the pattern of DDCs
staining for HLA-DR and factor Xllla, i.e. coex-
pression as well as cells with restricted staining
with both antibodies, purely restricted staining
within DDCs for either CD34 or factor Xllla, and
cells with either CD34 or HLA-DR expression, we
are confident that al! of the binding sites on the
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initial polyspecific secondary antibody were ade-
quately blocked by the avidin-biotin amplification
system such that no sites were available for cross
reacti\'ity.
In most radial and vertical growth-phase
melanomas, HLA-DR expressing DDCs were
found in association with the host lymphocytic in-
flammatory response and, more importantly, ap-
peared to be associated with a brisk and infiltrative
lymphocytic response as described by Elder and
coworkers (22, 23). This finding may further sup-
port a putative antigen-presenting role by DDCs to
tumor infiltrating lymphocytes.
The DDC remains an under studied cell in the
dermal immune response to the wide range of in-
flammatory and neoplastic processes that involve
the skin. Additional studies of HLA-DR-expressing
DDCs in melanomas with a brisk and infiltrative
lymphocytic host response compared to melano-
mas with a brisk and noninfiltrative, nonbrisk, or
absent lymphocytic host response should be done.
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